Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer

OBJECTIVE: The clinical efficacy and safety profile of trastuzumab deruxtecan (T-DXd) have been demonstrated in previously treated patients with human epidermal growth factor receptor 2 (HER2)-low advanced breast cancer (BC). It is, however, necessary to evaluate the value of T-DXd considering both...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Demin, Liang, Xueyan, Li, Yan, Chen, Lingyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449172/
https://www.ncbi.nlm.nih.gov/pubmed/37616309
http://dx.doi.org/10.1371/journal.pone.0290507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449172/
https://www.ncbi.nlm.nih.gov/pubmed/37616309
http://dx.doi.org/10.1371/journal.pone.0290507

Ejemplares similares